Evidence map›Paper›PMID 28150217›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2017

Nanoparticle-Mediated X-Ray Radiation Enhancement for Cancer Therapy.

Autumn D Paro, Ilanchezhian Shanmugam, Anne L van de Ven

Abstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Radiosensitization effects by bismuth oxide nanorods of different sizes in megavoltage external beam radiotherapy.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2021
    Article
  9. Review
  10. Improving Brain Tumor Treatment through Nanotechnology and Proton Therapy Using Laser-driven Accelerators through GEANT4 Simulation.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Autumn D ParoDepartment of Chemical Engineering, Northeastern University, Boston, MA, USA.
Ilanchezhian ShanmugamNanomedicine Science & Technology Center, Northeastern University, Boston, MA, USA.
Anne L van de VenNanomedicine Science & Technology Center, Northeastern University, Boston, MA, USA. a.vandevenmoloney@northeastern.edu.

Funding

CaNCURE: Cancer Nanomedicine Co-ops For Undergraduate Research ExperiencesR25CA174650 · NCI · NORTHEASTERN UNIVERSITY · PI SRINIVAS SRIDHAR · 2014 to 2026
$3.4M
NCI NIH HHS R25 CA174650
6 · The paper itself

Abstract

Metallic nanoparticles with a high atomic number release Auger electrons in response to external beam X-ray radiation. When these nanoparticles are selectively delivered to tumors, they have the potential to locally enhance the effects of radiation therapy. Optimizing the therapeutic efficacy of these nanoparticles, however, remains a challenging and time-consuming task. Here we describe three different assays that can be used to experimentally quantify and optimize the in vitro therapeutic efficacy of nanoparticle-mediated X-ray radiation enhancement. These include an IC50 extended dose response curve, clonogenic cell survival assay, and immunoblotting. Collectively, these assays provide information about whether a given nanoparticle provides radiosensitization, the extent of the radiosensitization, and the potential mechanism of radiosensitization.

Indexed as

Metal NanoparticlesRadiation-Sensitizing AgentsX-RaysBiomarkersCell Line, TumorCell SurvivalDose-Response Relationship, RadiationHumansInhibitory Concentration 50NeoplasmsTumor Stem Cell AssayBiomarkersRadiation-Sensitizing AgentsClonogenic assayDNA damageIC50ImmunoblottingMetallic nanoparticlesRadiosensitizationSurviving fraction

Identifiers

PMID28150217
PMCPMC5512559

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.